Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05218083 · ClinicalTrials.gov registry record · NA

REmotely Monitored, Mobile Health Supported Multidomain Rehabilitation Program With High Intensity Interval Training for COVID-19

A NA study of COVID-19 and Critical Illness, sponsored by Duke University.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
5
Study locations

NCT05218083: Recruiting NA study of COVID-19 and Critical Illness, sponsored by Duke University.

NCT05218083 is a NA study of COVID-19 and Critical Illness that is actively recruiting participants, run by Duke University. The registered enrollment target is 120 participants, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05218083, a NA study of COVID-19 and Critical Illness, is actively recruiting participants, sponsored by Duke University.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
5
Study locations

Study Summary

Multicenter, prospective, randomized controlled trial providing mobile health supported physical rehabilitation to 120 patients who have been critically ill with COVID-19 and who complete at least one exercise session.

Primary Outcome

distance walked in m

Interventions

  • BEHAVIORAL REmotely monitored, Mobile health supported Multidomain Rehabilitation Program with High Intensity Interval Training (REMM-HIIT)

Study Locations (5)

Alabama

  • University of Alabama at Birmingham - Birmingham

Kentucky

  • University of Kentucky - Lexington

North Carolina

  • Duke University Health System - Durham

Ohio

  • The Ohio State University Wexner Medical Center - Columbus

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2023-02-23
Est. Completion 2026-11-01
Phase NA
Duke University

1,725 total trials

What NCT05218083 shows while recruiting

NCT05218083 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).

The record links to 5 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which REmotely monitored, Mobile health supported Multidomain Rehabilitation Program with High Intensity Interval Training (REMM-HIIT) is the first listed.

NCT05218083 lists 5 locations in 5 states (Alabama, Kentucky, North Carolina).

Frequently Asked Questions

What is clinical trial NCT05218083 about?

NCT05218083 is a clinical study titled "REmotely Monitored, Mobile Health Supported Multidomain Rehabilitation Program With High Intensity Interval Training for COVID-19". Multicenter, prospective, randomized controlled trial providing mobile health supported physical rehabilitation to 120 patients who have been critically ill with COVID-19 and who complete at least one exercise session.

What is the current status of trial NCT05218083?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2023-02-23. Estimated completion is 2026-11-01.

What conditions does trial NCT05218083 study?

This clinical trial studies the following conditions: COVID-19, Critical Illness, ICU Acquired Weakness, Cardiorespiratory Fitness, PICS.

What interventions are being tested in trial NCT05218083?

The interventions under investigation include: REmotely monitored, Mobile health supported Multidomain Rehabilitation Program with High Intensity Interval Training (REMM-HIIT) (BEHAVIORAL).

Who is sponsoring clinical trial NCT05218083?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05218083 being conducted?

This trial has 5 study locations across Alabama, Kentucky, North Carolina, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05218083's enrollment target sits among peer trials

120 189th of 298 higher than 110 of 298 other COVID-19 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05218083, the US trial registry maintained by the National Library of Medicine. NCT05218083 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.